Form 8-K - Current report:
SEC Accession No. 0001493152-24-043241
Filing Date
2024-10-31
Accepted
2024-10-31 17:20:02
Documents
14
Period of Report
2024-10-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46588
2 ex10-1.htm EX-10.1 96260
  Complete submission text file 0001493152-24-043241.txt   336216

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE evfm-20241027.xsd EX-101.SCH 3009
4 XBRL LABEL FILE evfm-20241027_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE evfm-20241027_pre.xml EX-101.PRE 24161
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3587
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 241416215
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)